NL8502100A - Middel voor de behandeling van hypotrofe toestanden. - Google Patents
Middel voor de behandeling van hypotrofe toestanden. Download PDFInfo
- Publication number
- NL8502100A NL8502100A NL8502100A NL8502100A NL8502100A NL 8502100 A NL8502100 A NL 8502100A NL 8502100 A NL8502100 A NL 8502100A NL 8502100 A NL8502100 A NL 8502100A NL 8502100 A NL8502100 A NL 8502100A
- Authority
- NL
- Netherlands
- Prior art keywords
- arginine
- treatment
- children
- dose
- hypotrophic
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 12
- 239000004475 Arginine Substances 0.000 claims description 15
- 229960003121 arginine Drugs 0.000 claims description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 15
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims description 12
- 229960002223 arginine aspartate Drugs 0.000 claims description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 10
- 206010053759 Growth retardation Diseases 0.000 claims description 8
- 231100000001 growth retardation Toxicity 0.000 claims description 8
- 230000000729 hypotrophic effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 230000002354 daily effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 101710144202 Probable soluble pyridine nucleotide transhydrogenase Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 102100028023 Saitohin Human genes 0.000 description 9
- 101710165942 Soluble pyridine nucleotide transhydrogenase Proteins 0.000 description 9
- 230000028327 secretion Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 102000018997 Growth Hormone Human genes 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000000122 growth hormone Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 102000051325 Glucagon Human genes 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 101100107642 Arabidopsis thaliana ABI4 gene Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000064 subacute toxicity study Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8411835 | 1984-07-24 | ||
| FR8411835A FR2568124B1 (fr) | 1984-07-24 | 1984-07-24 | Medicament pour traiter les etats hypotrophiques par administrations d'aspartate d'arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8502100A true NL8502100A (nl) | 1986-02-17 |
Family
ID=9306499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8502100A NL8502100A (nl) | 1984-07-24 | 1985-07-22 | Middel voor de behandeling van hypotrofe toestanden. |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS6137734A (it) |
| AU (1) | AU574811B2 (it) |
| BE (1) | BE902954A (it) |
| CH (1) | CH660689A5 (it) |
| DE (1) | DE3439805C2 (it) |
| DZ (1) | DZ699A1 (it) |
| FR (1) | FR2568124B1 (it) |
| IT (1) | IT1177368B (it) |
| LU (1) | LU86020A1 (it) |
| MA (1) | MA20290A1 (it) |
| NL (1) | NL8502100A (it) |
| OA (1) | OA07878A (it) |
| PT (1) | PT79617A (it) |
| ZA (1) | ZA851683B (it) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019558A (en) * | 1988-05-09 | 1991-05-28 | Georges Cehovic | Method for treating memory disturbances using arginine aspartate |
| DE19705233A1 (de) * | 1997-02-12 | 1998-08-13 | Froelich Juergen C | Verfahren zur Herstellung einer Formulierung enthaltend Arginin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR106F (it) * | 1964-12-21 | |||
| IT1131854B (it) * | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per uso terapeutico,per uso diagnostico e quale integratore alimentare |
| FR2547501A1 (fr) * | 1983-06-15 | 1984-12-21 | Opochimiotherapie Lab | Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants |
-
1984
- 1984-07-24 FR FR8411835A patent/FR2568124B1/fr not_active Expired
- 1984-10-31 DE DE3439805A patent/DE3439805C2/de not_active Expired - Lifetime
- 1984-11-10 DZ DZ847325A patent/DZ699A1/fr active
- 1984-11-19 JP JP24431884A patent/JPS6137734A/ja active Pending
- 1984-11-23 CH CH5615/84A patent/CH660689A5/fr not_active IP Right Cessation
- 1984-11-27 OA OA58455A patent/OA07878A/xx unknown
- 1984-11-29 IT IT23800/84A patent/IT1177368B/it active
- 1984-12-03 MA MA20514A patent/MA20290A1/fr unknown
- 1984-12-05 PT PT79617A patent/PT79617A/pt unknown
-
1985
- 1985-03-06 ZA ZA851683A patent/ZA851683B/xx unknown
- 1985-07-22 BE BE0/215391A patent/BE902954A/fr not_active IP Right Cessation
- 1985-07-22 NL NL8502100A patent/NL8502100A/nl not_active Application Discontinuation
- 1985-07-23 AU AU45273/85A patent/AU574811B2/en not_active Expired
- 1985-07-24 LU LU86020A patent/LU86020A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT79617A (en) | 1985-01-01 |
| FR2568124A1 (fr) | 1986-01-31 |
| IT8423800A1 (it) | 1986-05-29 |
| DE3439805A1 (de) | 1986-02-06 |
| DE3439805C2 (de) | 1994-01-20 |
| BE902954A (fr) | 1986-01-22 |
| FR2568124B1 (fr) | 1988-12-09 |
| LU86020A1 (fr) | 1986-02-12 |
| DZ699A1 (fr) | 2004-09-13 |
| MA20290A1 (fr) | 1985-07-01 |
| AU574811B2 (en) | 1988-07-14 |
| ZA851683B (en) | 1986-01-29 |
| CH660689A5 (fr) | 1987-06-15 |
| AU4527385A (en) | 1986-01-30 |
| IT1177368B (it) | 1987-08-26 |
| OA07878A (fr) | 1986-11-20 |
| JPS6137734A (ja) | 1986-02-22 |
| IT8423800A0 (it) | 1984-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Astwood | Growth hormone and corticotropin | |
| Barbul | Arginine: biochemistry, physiology, and therapeutic implications | |
| Barbuio et al. | Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet | |
| CA2191677C (en) | Cerebral function improving agents | |
| US6420350B1 (en) | Weight loss product | |
| CN1329030C (zh) | 肝癌发生·发展抑制剂 | |
| CA2566343C (en) | Nutritional composition for increasing creatine uptake in skeletal muscle | |
| US20190038769A1 (en) | Micro-rna profiling, compositions, and methods of treating diseases | |
| JPH01216924A (ja) | 肝障害治療剤 | |
| CN111372586A (zh) | 包含chp的骨丢失疾病的预防、改善或治疗用组合物 | |
| Pickford et al. | The effect of adrenaline on secretion of cortical hormone in the hypophysectomized dog | |
| JP5833545B2 (ja) | 男性不妊の治療のための、ｄ−アスパラギン酸とｌ−アスパラギン酸またはこれら酸の塩の組み合わせの使用 | |
| EP2424527B1 (en) | Mast cell stabilizers to prevent or treat laminitis | |
| Hironao et al. | The cacao procyanidin extract-caused anti-hyperglycemic effect was changed by the administration timings | |
| Glick | Modes of action of gallic acid in suppressing food intake of rats | |
| DRAGSTEDT et al. | Lipocaic and fatty infiltration of the liver in pancreatic diabetes | |
| KR100304312B1 (ko) | 아연이보충된전립선추출물 | |
| Tsuchiya et al. | Milk-derived lactoferrin may block tolerance to morphine analgesia | |
| Sugiura et al. | The influence of hormones on the growth of carcinoma, sarcoma, and melanoma in animals | |
| AU8076691A (en) | Process for activating reproduction of seasonal breeding animals by administering l-dihydroxyphenylalanine (l-dopa) | |
| Lansford Jr et al. | Effects of asparagine and other related nutritional supplements upon alcohol-induced rat liver triglyceride elevation | |
| Desai et al. | Branched-chain amino acid administration in surgical patients: effects on amino acid and fuel substrate profiles | |
| Birkhahn et al. | Potential of the monoglyceride and triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and preliminary biological testing in the rat | |
| Leblond | Iodine metabolism | |
| Potter et al. | Possible role of hydrazine group in hypoglycemia associated with the use of certain monoamine-oxidase inhibitors (MAOI's) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| CNR | Transfer of rights (patent application after its laying open for public inspection) |
Free format text: LABORATOIRES SARGET S.A.;LABORATOIRES SARGET S.A. |
|
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: ASTA MEDICA;ASTA MEDICA |
|
| BV | The patent application has lapsed |